Expression of Concern: Paladugu et al. Liraglutide Has Anti-Inflammatory and Anti-Amyloid Properties in Streptozotocin-Induced and 5xFAD Mouse Models of Alzheimer’s Disease. Int. J. Mol. Sci. 2021, 22, 860
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsAlzheimer's disease research and treatments · Cancer-related cognitive impairment studies · Cholinesterase and Neurodegenerative Diseases
With this notice, the Internation Journal of Molecular Sciences Editorial Office states their awareness of the concerns regarding the integrity of a number of the figures published within this publication [1]. Following discussion with the authors and a representative from the Central Michigan University, the Editorial Board has decided to allow the authors to confirm the validity of the overall findings by performing re-experimentation on certain elements of this study. As such, this Expression of Concern will stay in place until this process has been completed, and the Editorial Office will provide an update on this situation and announce any post-publication modifications deemed to be necessary, as per MDPI’s Update to Published Papers policy.
The reference list from the paper itself. Each links out to its DOI / PubMed record.
- 1Paladugu L. Gharaibeh A. Kolli N. Learman C. Hall T.C. Li L. Rossignol J. Maiti P. Dunbar G.L. Liraglutide Has Anti-Inflammatory and Anti-Amyloid Properties in Streptozotocin-Induced and 5x FAD Mouse Models of Alzheimer’s Disease Int. J. Mol. Sci.20212286010.3390/ijms 2202086033467075 PMC 7829894 · doi ↗ · pubmed ↗